Logo

Amgen Launches Amgevita (adalimumab- biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

Share this
Amgen Launches Amgevita (adalimumab- biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

Amgen Launches Amgevita (adalimumab- biosimilar) in EU to Treat Inflammatory Diseases post EMA Approval in Feb 2017

Shots:
  • Amgevita will be launched in 28 EU countries as well as Norway- Iceland and Liechtenstein making it 3rd EU Amgen's approved biosimilar
  • EMA approved Amgevita in RA- PsA- AS- nr-axSpA- plague psoriasis- HS- non-infectious panuveitis- CD and UC in adults and CD- plague psoriasis- ERA and JIA in pediatric patients
  • Amgevita is an IgG1 mAb that deactivates TNFα and is available in a prefilled syringe & pen (SureClick autoinjector) for approved dosing in multiple indications
Ref: Amgen  | Image: Contract Pharma

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions